Results 71 to 80 of about 39,650 (248)

Hyper‐Intense Tumor Peripheral Accumulation of Antibody‐Conjugated Iron Oxide Nanoparticles can Enable Breast Cancer Detection by Magnetic Particle Imaging

open access: yesAdvanced Science, EarlyView.
Tumor‐associated inflammation retains antibody‐targeted or non‐specific antibody conjugated nanoparticles within the tumor microenvironment. Magnetic Particle Imaging (MPI) enables non‐invasive detection and differentiation of tumors from other organs, owing to higher nanoparticle retention by inflammatory cells in the tumor periphery.
Preethi Korangath   +9 more
wiley   +1 more source

Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy

open access: yesDrug Delivery, 2018
The efficacy of traditional chemotherapy often suffers from rapid clearance and off-target toxicity. Drug delivery systems and controlled release are applied to improve the therapeutic efficiencies of small-molecule drugs.
Jincheng Yang   +8 more
doaj   +1 more source

Preparation of Water-Soluble Maleimide-Functionalized 3 nm Gold Nanoparticles: A New Bioconjugation Template

open access: yes, 2016
We present an efficient methodology to prepare maleimide-tethered, water-soluble gold nanoparticles (maleimide-AuNPs). The maleimide-AuNPs were prepared in the protected form and are readily recovered via a retro-Diels–Alder reaction. The maleimide-AuNPs
Jun Zhu (84054)   +3 more
core   +1 more source

Ultrasound‐Activated Nanoinhibitors Blocking the Chemo‐Immune Checkpoint to Overcome Chemotherapy‐Induced Immune Resistance

open access: yesAdvanced Science, EarlyView.
A sono‐responsive chemo‐immune checkpoint nanoinhibitor (Sono‐TT8) co‐delivering TPZ chemotherapy and siXkr8 simultaneously kills tumor cells and blocks PS externalization, reversing chemotherapy‐induced immunosuppression and enhancing antitumor immunity. ABSTRACT Breast cancer features an immunosuppressive tumor microenvironment following chemotherapy
Yunfan Liu   +13 more
wiley   +1 more source

Spatiotemporally Controlled Sequential Chemo‐Immunotherapy Activates Pyroptosis for Robust Anti‐Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
A glutathione and ultrasound dual‐responsive cerasome achieves sequential co‐delivery of gemcitabine and BMS1166 in tumors. Chemotherapy priming followed by on‐demand PD‐L1 blockade synergistically amplifies anti‐tumor immunity, inhibiting primary tumor growth, distant metastasis and inducing durable immune memory.
Suhui Sun   +9 more
wiley   +1 more source

Pervaporation of Ethanol and Water Through Polymeric Membranes with Incorporated N-(Halogenophenyl)maleimide Units

open access: yes, 1994
Styrene N-(chloro- or bromophenyl)maleimide and methyl methacrylate N-(chloro- or bromophenyl)maleimide copolymers were synthesized. Membranes casted from the copolymer solutions were used for the pervaporation of ethanol water mixtures at 35 °C.
Jitka Bílá, Jan Lokaj
core   +1 more source

Sonogenetics Nanomedicine Activates the cGAS‐STING Pathway for Immunotherapy of Triple‐Negative Breast Cancer

open access: yesAdvanced Science, EarlyView.
A HER3‐targeted sonogenetic lipid nanoparticle platform is developed for triple‐negative breast cancer therapy. An AI‐designed miniprotein inhibits HER3 signaling, while TRPV4 and NFAT‐responsive IL‐15 plasmids enable ultrasound‐controlled calcium signaling and cytokine expression. The system induces Ca2+ overload, ROS generation, mitochondrial damage,
Junya Song   +6 more
wiley   +1 more source

Design and Synthesis of Novel “Orthogonally” Functionalizable Maleimide‐Based Styrenic Copolymers

open access: yes, 2012
Polymers containing maleimide groups on their side chains have been synthesized by utilization of a novel styrenic monomer containing a masked-maleimide unit.
Amitav Sanyal   +5 more
core   +1 more source

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

open access: yesAdvanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen   +10 more
wiley   +1 more source

N-(4-Nitrophenyl)-2-{2-[3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetamide

open access: yesMolbank, 2017
In the present investigation, the synthesis and spectroscopic characterization of N-(4-nitrophenyl)-2-{2-[3-(4-chlorophenyl)-5-[4-(propan-2-yl)phenyl]-4,5-dihydro-1H-pyrazol-1-yl]-4-oxo-4,5-dihydro-1,3-thiazol-5-yl}acetamide (2) is performed.
Vinutha V. Salian   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy